News for Abbott Laboratories (ABT)

CNBC's Jim Cramer's on Friday told investors what to follow next week as earnings season kicks off.

On June 30, 2025, Vanguard Group Inc. made a significant move by acquiring an additional 3,348,838 shares of AbbVie Inc. (NYSE: ABBV) at a price of $185.62 per

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Reckitt Benckiser Group Plc (”œReckitt

Citi's analyst, Joanne Wuensch, has increased the price target for Abbott (ABT) from $155 to $157 while maintaining a Buy rating on the company's shares. This a

Abbott Laboratories (NYSE:ABT) is one of the top 10 defensive stocks to consider in a volatile market.

Abbott Laboratories (NYSE:ABT) is one of the top 10 defensive stocks to consider in a volatile market. On July 3, analysts at Oppenheimer reiterated an ‘Outperform’ rating on the stock and a $14 price target. The bullish stance follows the Centers for Medicare & Medicaid Services (CMS) final decision on transcatheter edge-to-edge repair for the […]

Is ABT stock still a good investment? We contend that it is.

Get the latest stock market news: Stock movers, top-performing sectors, and popular stock activity. Stay ahead with a quick and comprehensive market rundown.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

PR NewswireNEW YORK, July 7, 2025 NEW YORK, July 7, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Reckitt

Absci (ABSI) appoints veteran biopharma executive Mary Szela to its Board of Directors. Two key pipeline programs underway: ABS-101 (Phase 1 expected in 202

PR NewswireNEW YORK, July 2, 2025 NEW YORK, July 2, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Reckitt

Get the latest stock market news: Stock movers, top-performing sectors, and popular stock activity. Stay ahead with a quick and comprehensive market rundown.

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Policies associated with the MAHA movement could boost these two stocks significantly.

Abbott is poised to release its second-quarter results next month, and analysts project a single-digit earnings growth.

Key collaborations enable Abbott to increase its global presence and accessibility to patients who haven't used CGMs before. Read why ABT stock is a Buy.

Incredible as that was, this week could have easily went another way.

NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Reckitt Benckiser Group Plc (”œReckitt